BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32651695)

  • 21. The impact of race/ethnicity on pancreaticoduodenectomy outcomes for pancreatic cancer.
    Alwatari Y; Mosquera CM; Khoraki J; Rustom S; Wall N; Sevdalis AE; Stover W; Trevino JG; Kaplan B
    J Surg Oncol; 2023 Jan; 127(1):99-108. PubMed ID: 36177773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multimodality management of borderline resectable pancreatic adenocarcinoma.
    Prakash LR; Katz MHG
    Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
    Schwarz L; Katz MH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A replaced right hepatic artery adjacent to pancreatic carcinoma should be divided to obtain R0 resection in pancreaticoduodenectomy.
    Okada K; Kawai M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Tani M; Yamaue H
    Langenbecks Arch Surg; 2015 Jan; 400(1):57-65. PubMed ID: 25359559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
    Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals.
    Olecki EJ; Perez Holguin RA; Mayhew MM; Wong WG; Vining CC; Peng JS; Shen C; Dixon MEB
    J Surg Res; 2024 Feb; 294():160-168. PubMed ID: 37897875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study.
    Aadam AA; Evans DB; Khan A; Oh Y; Dua K
    Gastrointest Endosc; 2012 Jul; 76(1):67-75. PubMed ID: 22483859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare disparities in outcomes of patients with resectable pancreatic cancer.
    Moaven O; Richman JS; Reddy S; Wang T; Heslin MJ; Contreras CM
    Am J Surg; 2019 Apr; 217(4):725-731. PubMed ID: 30583797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2).
    Farnes I; Kleive D; Verbeke CS; Aabakken L; Issa-Epe A; Småstuen MC; Fosby BV; Dueland S; Line PD; Labori KJ
    BJS Open; 2023 Nov; 7(6):. PubMed ID: 38155512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
    Wang G; Zhou D
    Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
    Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
    BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.
    Sohn TA; Yeo CJ; Cameron JL; Koniaris L; Kaushal S; Abrams RA; Sauter PK; Coleman J; Hruban RH; Lillemoe KD
    J Gastrointest Surg; 2000; 4(6):567-79. PubMed ID: 11307091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
    Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
    BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.